5Hansson L,Zanchetti A,Carruthers SG,et al.Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension; principal results of the hypertension optimal treatment (HOT) randomized trial.HOT Study Group[J].Lancet,1998,351:1755-1762.
6UK Prospective Diabetes Study Group.Tight blood pressure control and risk of microvascular and macrovascular complications in type 2 diabetes:UKPDS 38[J].BMJ,1998,317:703-713.
7Cooper ME,Johnston CL.Optimizing treatment of hypertension in patients with diabetes[J].JAMA,2000,283(24):3177-3186.
4UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38.BMJ 1998;317:703.
5Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment(HOT) randomised trial. Lancet 1998;351:1755.
6The Heart Outcomes Prevention Evaluation Investigation.Effects of anangiotension converting enzyme inhibitor, ramipril, on cardiovascular events in hith risk patients. N Engl J Med 2000:342:145.
7Mc Garry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes Diabetes 2001 ;50(Suppl 2):6.
8Grundy SM, Benjamin CI, Burke GL, et al. Diabetes and cardiovascular diseases. Circulation 1999 ; 100 : 1134.
9Turner RC, Millns H, Neil HA, et al. Risk factors for coronary arteery disease in non-insulin-dependent diabetes mellitus(UKPDS:23) .BMJ 1998;316:823.
10American diabetes association. Management of dyslipidemia in adults with diabetes.Diabetes Care 2000;23:319.
1Frans Hh,Leenen,Elizabeth,et al.Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients:amlodipine versus felodipine extended release[J].Journal of hypertension,2006,24(1):231-237.
2Liyuan,Ma,Wen,Wang,Yong,Zhao,Yuqing,et al.Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients:a 96-week efficacy and safety study[J].American journal of cardiovascular drugs:drugs,devices,and other interventions,2012,12(2):23-31.
